Russian pharmaceutical company Sotex has presented the results of the world’s first meta-analysis on the use of hymecromone as monotherapy. The data were unveiled at the 30th anniversary International Congress “Hepatology Today” held in Moscow on March 20–21.
Professor Olga Zolnikova, chief gastroenterologist for Russia’s Central Federal District, delivered a report on the clinical features of gallstone disease in patients with non-alcoholic fatty liver disease (NAFLD). In her presentation, Zolnikova cited data on current understanding of the link between gallstone disease and NAFLD, and outlined how the disease presents in patients with these coexisting conditions. The expert paid particular attention to the role of selective antispasmodics, including hymecromone, which is recognized as a first-line treatment based on several clinical criteria.
The meta-analysis included data from more than 1,100 patients, providing a robust evidence base for key indicators of hymecromone used as monotherapy, the company said. The researchers also presented new data on combining hymecromone with ursodeoxycholic acid — a combination intended to boost treatment efficacy and improve tolerability.
The specialists also highlighted emerging data on the molecule’s additional properties — antifungal, antibacterial, anti-inflammatory and antifibrotic, they said. These findings open new prospects for expanding the drug’s indications, they stressed.